Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether combination treatment (adding
methylprednisolone to Avonex) reduces progression of disability over 4 years compared to
Avonex alone. The study will also investigate whether combination therapy has any impact on
the incidence of relapse and brain atrophy as measured by MRI.